TABLE 1.
Patient characteristics
| Responder | Non‐responder | |
|---|---|---|
| Total, n | 3 | 6 |
| Age, years (range) | 68.0 (59–76) | 69.3 (59–75) |
| Sex (Male/Female) | (3/0) | (3/3) |
| Smoking history (never/prior·current) | (0/3) | (0/6) |
| ECOG PS (0–1/2–4) | (3/0) | (1/5) |
| Stage IV disease (de novo/recurrent) | (1/2) | (6/0) |
| Initial treatment cycles | 5.3 (4–6) | 1.8 (1–3) |
| CEA (ng/ml) | 145.1 (5.0–407.0) | 192.2 (2.0–1126.0) |
| (≦5.0/>5.0) | (2/1) | (4/2) |
| Pro‐GRP (ng/ml) | 198.8 (62.4–431.0) | 493.5 (18.0–1470.0) |
| (≦81.0/>81.0) | (2/1) | (3/3) |
| NSE (ng/ml) | 13.1 (11.4–16.2) | 116.7 (9.3–351.0) |
| (≦16.3/>16.3) | (0/3) | (3/1) |
| Distant metastasis | ||
| Brain metastasis (yes/no) | (0/3) | (4/2) |
| Distant metastasis in 2 organs (yes/no) | (0/3) | (5/1) |
| PD‐L1 expression (22C3) (low/high/untested) | (1/0/2) | (4/0/2) |
Abbreviations: CEA, carcinoembryonic antigen; ECOG PS, Eastern Cooperative Oncology Group Performance Status; NSE, neuron‐specific enolase; Pro‐GRP, pro‐gastrin‐releasing peptide; Recurrent, denotes patients who were diagnosed with Stage I/II at initial diagnosis, underwent surgical resection, and then recurred.